Ntyl Tablet is a pharmaceutical formulation combining Acetylcysteine 600 mg and Pyridoxamine dihydrochloride 50 mg, designed to provide mucolytic and antioxidant benefits alongside advanced glycation end-product inhibition. Acetylcysteine, a well-established mucolytic agent, acts by disrupting disulfide bonds in mucus glycoproteins, thereby reducing mucus viscosity and facilitating expectoration in respiratory conditions such as chronic bronchitis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). Additionally, Acetylcysteine serves as a precursor to glutathione, a critical intracellular antioxidant that helps mitigate oxidative stress and cellular damage. Pyridoxamine dihydrochloride, a derivative of vitamin B6, exhibits potent antiglycation properties by scavenging reactive carbonyl intermediates and inhibiting the formation of advanced glycation end-products (AGEs), which are implicated in the pathogenesis of diabetic complications, renal dysfunction, and vascular damage. The synergistic combination of these two active ingredients in Ntyl Tablet offers a dual therapeutic approach by enhancing mucolysis and protecting tissues from oxidative and glycation-related injury. Ntyl Tablet is indicated for use in patients requiring mucolytic therapy with concurrent risk or presence of glycation-associated disorders. It should be administered under medical supervision, with dosage adjusted according to clinical response and patient tolerance.